Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Florbetaben Clear all
Terminated Early Phase 1 Interventional

Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT

NCT04105634
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
FNOS, Florbetaben
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed No phase listed Observational

Florbetaben PET Imaging in PPA

NCT04720001
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease
Interventions
Florbetaben F18, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT07169630
View directory record Official record
Conditions
Alzheimer s Disease, Mild Cognitive Impairment, Healthy
Interventions
18F-PF974, 18F-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
50 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026
View directory record Official record
Conditions
Tauopathies
Interventions
11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

NCT00928304
View directory record Official record
Conditions
Down Syndrome, Amyloid Beta-protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 10, 2026, 4:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169
View directory record Official record
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease

NCT02831283
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
Drug · Procedure
Lead sponsor
Patrick Lao
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

NCT05337774
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
[18F]PI-2620
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
25 Years to 54 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

NCT03744312
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, Florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology

NCT01020838
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Sun City, Arizona • Stanford, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
View directory record Official record
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360
View directory record Official record
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 10, 2026, 4:14 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion

NCT05270083
View directory record Official record
Conditions
Concussion, Brain
Interventions
NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

NCT01222351
View directory record Official record
Conditions
Late Onset Alzheimer Disease
Interventions
BAY 94-9172 (Florbetaben)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
65 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced Sep 10, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Vascular Disease in Aging and Dementia

NCT03075007
View directory record Official record
Conditions
Alzheimer Disease, White Matter Hyperintensities, Dementia, Aging
Interventions
Florbetaben F18, Transcranial Doppler
Radiation · Procedure
Lead sponsor
Columbia University
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 10, 2026, 4:14 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Alzheimer's Disease Research Center (ADRC) PET Component Study

NCT07758660
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Dementia
Interventions
18F-MK6240, 18F-Florbetaben (FBB)
Drug
Lead sponsor
Patrick Lao
Other
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
View directory record Official record
Conditions
Parkinson's Disease, Dementia, Alzheimer's Disease, ALS, Mild Cognitive Impairment
Interventions
11C-MC1, 11C-PS13, 18f-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 4:14 PM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 10, 2026, 4:14 PM EDT